Cargando…

Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer

BACKGROUND: Interferon gamma (IFNγ) is a pro-inflammatory cytokine that directly activates the JAK/STAT pathway. However, the temporal dynamics of chromatin remodeling and transcriptional activation initiated by IFNγ have not been systematically profiled in an unbiased manner. Herein, we integrated...

Descripción completa

Detalles Bibliográficos
Autores principales: Hogg, Simon J., Motorna, Olga, Kearney, Conor J., Derrick, Emily B., House, Imran G., Todorovski, Izabela, Kelly, Madison J., Zethoven, Magnus, Bromberg, Kenneth D., Lai, Albert, Beavis, Paul A., Shortt, Jake, Johnstone, Ricky W., Vervoort, Stephin J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336046/
https://www.ncbi.nlm.nih.gov/pubmed/35902886
http://dx.doi.org/10.1186/s13148-022-01316-5
_version_ 1784759460760125440
author Hogg, Simon J.
Motorna, Olga
Kearney, Conor J.
Derrick, Emily B.
House, Imran G.
Todorovski, Izabela
Kelly, Madison J.
Zethoven, Magnus
Bromberg, Kenneth D.
Lai, Albert
Beavis, Paul A.
Shortt, Jake
Johnstone, Ricky W.
Vervoort, Stephin J.
author_facet Hogg, Simon J.
Motorna, Olga
Kearney, Conor J.
Derrick, Emily B.
House, Imran G.
Todorovski, Izabela
Kelly, Madison J.
Zethoven, Magnus
Bromberg, Kenneth D.
Lai, Albert
Beavis, Paul A.
Shortt, Jake
Johnstone, Ricky W.
Vervoort, Stephin J.
author_sort Hogg, Simon J.
collection PubMed
description BACKGROUND: Interferon gamma (IFNγ) is a pro-inflammatory cytokine that directly activates the JAK/STAT pathway. However, the temporal dynamics of chromatin remodeling and transcriptional activation initiated by IFNγ have not been systematically profiled in an unbiased manner. Herein, we integrated transcriptomic and epigenomic profiling to characterize the acute epigenetic changes induced by IFNγ stimulation in a murine breast cancer model. RESULTS: We identified de novo activation of cis-regulatory elements bound by Irf1 that were characterized by increased chromatin accessibility, differential usage of pro-inflammatory enhancers, and downstream recruitment of BET proteins and RNA polymerase II. To functionally validate this hierarchical model of IFNγ-driven transcription, we applied selective antagonists of histone acetyltransferases P300/CBP or acetyl-lysine readers of the BET family. This highlighted that histone acetylation is an antecedent event in IFNγ-driven transcription, whereby targeting of P300/CBP acetyltransferase activity but not BET inhibition could curtail the epigenetic remodeling induced by IFNγ through suppression of Irf1 transactivation. CONCLUSIONS: These data highlight the ability for epigenetic therapies to reprogram pro-inflammatory gene expression, which may have therapeutic implications for anti-tumor immunity and inflammatory diseases. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-022-01316-5.
format Online
Article
Text
id pubmed-9336046
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-93360462022-07-30 Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer Hogg, Simon J. Motorna, Olga Kearney, Conor J. Derrick, Emily B. House, Imran G. Todorovski, Izabela Kelly, Madison J. Zethoven, Magnus Bromberg, Kenneth D. Lai, Albert Beavis, Paul A. Shortt, Jake Johnstone, Ricky W. Vervoort, Stephin J. Clin Epigenetics Research BACKGROUND: Interferon gamma (IFNγ) is a pro-inflammatory cytokine that directly activates the JAK/STAT pathway. However, the temporal dynamics of chromatin remodeling and transcriptional activation initiated by IFNγ have not been systematically profiled in an unbiased manner. Herein, we integrated transcriptomic and epigenomic profiling to characterize the acute epigenetic changes induced by IFNγ stimulation in a murine breast cancer model. RESULTS: We identified de novo activation of cis-regulatory elements bound by Irf1 that were characterized by increased chromatin accessibility, differential usage of pro-inflammatory enhancers, and downstream recruitment of BET proteins and RNA polymerase II. To functionally validate this hierarchical model of IFNγ-driven transcription, we applied selective antagonists of histone acetyltransferases P300/CBP or acetyl-lysine readers of the BET family. This highlighted that histone acetylation is an antecedent event in IFNγ-driven transcription, whereby targeting of P300/CBP acetyltransferase activity but not BET inhibition could curtail the epigenetic remodeling induced by IFNγ through suppression of Irf1 transactivation. CONCLUSIONS: These data highlight the ability for epigenetic therapies to reprogram pro-inflammatory gene expression, which may have therapeutic implications for anti-tumor immunity and inflammatory diseases. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13148-022-01316-5. BioMed Central 2022-07-28 /pmc/articles/PMC9336046/ /pubmed/35902886 http://dx.doi.org/10.1186/s13148-022-01316-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Hogg, Simon J.
Motorna, Olga
Kearney, Conor J.
Derrick, Emily B.
House, Imran G.
Todorovski, Izabela
Kelly, Madison J.
Zethoven, Magnus
Bromberg, Kenneth D.
Lai, Albert
Beavis, Paul A.
Shortt, Jake
Johnstone, Ricky W.
Vervoort, Stephin J.
Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer
title Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer
title_full Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer
title_fullStr Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer
title_full_unstemmed Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer
title_short Distinct modulation of IFNγ-induced transcription by BET bromodomain and catalytic P300/CBP inhibition in breast cancer
title_sort distinct modulation of ifnγ-induced transcription by bet bromodomain and catalytic p300/cbp inhibition in breast cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9336046/
https://www.ncbi.nlm.nih.gov/pubmed/35902886
http://dx.doi.org/10.1186/s13148-022-01316-5
work_keys_str_mv AT hoggsimonj distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer
AT motornaolga distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer
AT kearneyconorj distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer
AT derrickemilyb distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer
AT houseimrang distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer
AT todorovskiizabela distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer
AT kellymadisonj distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer
AT zethovenmagnus distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer
AT brombergkennethd distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer
AT laialbert distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer
AT beavispaula distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer
AT shorttjake distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer
AT johnstonerickyw distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer
AT vervoortstephinj distinctmodulationofifnginducedtranscriptionbybetbromodomainandcatalyticp300cbpinhibitioninbreastcancer